Results 1 to 10 of about 117,912 (291)

Indications and Limitations of Sirolimus in the Treatment of Vascular Anomalies—Insights From a Retrospective Case Series

Frontiers in Pediatrics, 2022
BackgroundDespite recent developments, the role of sirolimus in the heterogeneous spectrum of vascular anomalies is yet to be defined, in terms of indication, dosage, and therapy duration, recognizing both its potential and limitations.MethodsWe ...
Anna Karastaneva, Paolo Gasparella, Sebastian Tschauner, Roman Crazzolara, Gabriele Kropshofer, Manfred Modl, Andreas Pfleger, Ante Burmas, Mirjam Pocivalnik, Raphael Ulreich, Werner Zenz, Wolfgang Schwinger, Besiana P. Beqo, Besiana P. Beqo, Christian Urban, Emir Q. Haxhija, Herwig Lackner, Martin Benesch   +17 more
doaj   +2 more sources

Oral antibiotic prophylaxis for infection in patients with vascular anomalies receiving sirolimus treatment: a multicenter retrospective study

Orphanet Journal of Rare Diseases, 2023
Objectives Patients with vascular anomalies (VAs) who receive oral sirolimus may be at high risk of infectious complications. Antibiotic prophylaxis with trimethoprim-sulfamethoxazole (TMP-SMZ) has been advocated.
Tong Qiu, Yanan Li, Xue Gong, Jiangyuan Zhou, Kaiying Yang, Xuepeng Zhang, Zixin Zhang, Yuru Lan, Fan Hu, Qiang Peng, Yongbo Zhang, Feiteng Kong, Siyuan Chen, Yi Ji   +13 more
doaj   +1 more source

Long-term efficacy and safety of sirolimus for retinal astrocytic hamartoma associated with tuberous sclerosis complex

Frontiers in Cell and Developmental Biology, 2022
Mammalian target of rapamycin (mTOR) inhibitors (sirolimus or everolimus) have been demonstrated effective in reducing the size of tuberous sclerosis complex (TSC)-associated retinal astrocytic hamartoma (RAH) in short term.
Chen-Xi Zhang, Kai-Feng Xu, Qin Long, Xiao Zhang, Zhi-Kun Yang, Rong-Ping Dai, Zhi-Qiao Zhang   +6 more
doaj   +1 more source

Quantification of sirolimus by liquid chromatography-tandem mass spectrometry using on-line solid-phase extraction [PDF]

, 2002
Quantification of the new immunosuppressant sirolimus (syn. rapamycin; Rapamune((R))) in whole blood by chromatography is essential for its clinical use since no immunoassay is available although monitoring is mandatory.
Fleischer, Claudia, Groetzner, Jan, Meiser, Bruno, Seidel, Dietrich, Spöhrer, Ute, Vogeser, Michael   +5 more
core   +1 more source

Sirolimus Pharmacokinetics Variability Points to the Relevance of Therapeutic Drug Monitoring in Pediatric Oncology

Pharmaceutics, 2021
Sirolimus is widely used in transplantation, where its therapeutic drug monitoring (TDM) is well established. Evidence of a crucial role for sirolimus in the PI3K/AkT/mTor pathway has stimulated interest in its involvement in neoplasia, either as ...
Amelia-Naomi Sabo, Sarah Jannier, Guillaume Becker, Jean-Marc Lessinger, Natacha Entz-Werlé, Véronique Kemmel   +5 more
doaj   +1 more source

Predicting sinusoidal obstruction syndrome after allogeneic stem cell transplantation with the EASIX biomarker panel [PDF]

, 2020
No biomarker panel is established for prediction of sinusoidal obstruction syndrome/veno-occlusive disease (SOS/VOD), a major complication of allogeneic stem cell transplantation (alloSCT).
Blau, Igor W., Bullinger, Lars, Dreger, Peter, Jiang, Sihe, Luft, Thomas, Majer-Lauterbach, Joshua, Müller-Tidow, Carsten, Penack, Olaf, Radujkovic, Aleksandar, Schult, David, Terzer, Tobias   +10 more
core   +3 more sources

Reduced risk of recurrent pneumothorax for sirolimus therapy after surgical pleural covering of entire lung in lymphangioleiomyomatosis

Orphanet Journal of Rare Diseases, 2021
Background Patients with lymphangioleiomyomatosis (LAM) frequently experience pneumothorax. Although sirolimus is the standard therapy for LAM, its effect on pneumothorax is controversial.
Teiko Sakurai, Toru Arai, Masaki Hirose, Kensuke Kojima, Tetsuki Sakamoto, Yoshinobu Matsuda, Chikatoshi Sugimoto, Hyung-Eun Yoon, Yoshikazu Inoue   +8 more
doaj   +1 more source

Dual mTOR/PI3K inhibition limits PI3K-dependent pathways activated upon mTOR inhibition in autosomal dominant polycystic kidney disease [PDF]

, 2018
Autosomal dominant polycystic kidney disease (ADPKD) is characterized by the development of kidney cysts leading to kidney failure in adulthood. Inhibition of mammalian target of rapamycin (mTOR) slows polycystic kidney disease (PKD) progression in ...
Arcaro, Alexandre, Castelletti, Deborah, Fu, Xuebin, Liu, Yang, Mischak, Harald, Mullen, William, Pejchinovski, Martin, Serra, Andreas L., Siwy, Justyna, Wang, Xueqi, Watnick, Terry J.   +10 more
core   +2 more sources

Pitfall in the high-throughput quantification of whole blood cyclosporin A using liquid chromatography-tandem mass spectrometry [PDF]

, 2005
In a growing number of laboratories the technique of liquid chromatography-tandem mass spectrometry is used for the quantification of cyclosporin A in whole blood, employing cyclosporin D as the internal standard. Cyclosporin A is extensively metabolized
Spöhrer, Ute, Vogeser, Michael
core   +2 more sources

Enhanced Supersaturation and Oral Absorption of Sirolimus Using an Amorphous Solid Dispersion Based on Eudragit® E

Molecules, 2015
The present study aimed to investigate the effect of Eudragit® E/HCl (E-SD) on the degradation of sirolimus in simulated gastric fluid (pH 1.2) and to develop a new oral formulation of sirolimus using E-SD solid dispersions to enhance oral ...
Youngseok Cho, Eun-Sol Ha, In-Hwan Baek, Min-Soo Kim, Cheong-Weon Cho, Sung-Joo Hwang   +5 more
doaj   +1 more source